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Abstract
Objective—To examine the association between state Medicaid vaccine administration fees and 
children’s receipt of immunization services.
Methods—The study used the 2008–2012 Medicaid Analytic eXtract data and included children 
aged 0–17 years and continuously enrolled in a Medicaid fee-for-service plan in each study year. 
Analyses were restricted to 8 states with a Medicaid managed-care penetration rate <75%. Linear 
regressions were used to estimate the probability of children making ≥1 vaccination visit and the 
numbers of vaccination visits in the year as a function of state Medicaid vaccine administration 
fees, age group, sex, race/ethnicity, state unemployment rate, state managed-care penetration rate, 
and state and year-fixed effects.
Results—A total of 1,678,288 children were included. In 2008–2012, the average proportion of 
children making ≥1 vaccination visit per year was 31% and the mean number of vaccination visits 
was 0.9. State Medicaid reimbursements for vaccine administration was positively associated with 
immunization service utilization; for every $1 increase in the payment amount, the probability of 
children making ≥ 1 vaccination visit increased by 0.72 percentage point (95% confidence 
interval, 0.23–1.21; P = 0.01), representing a 2% increase from the mean and the number of 
vaccination visits increased by 0.03 (95% confidence interval, −0.00 to 0.06; P < 0.1). The 
estimated effect was greater among younger children.
Conclusion—Higher Medicaid reimbursements for vaccine administration were associated with 
increased proportion of children receiving immunization services.
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Previous literature has demonstrated a strong positive association between health insurance 
coverage and medical care utilization.1–6 The results, however, are inconclusive when 
comparing access with medical care among publicly and privately insured children. For 
Reprints: Yuping Tsai, PhD, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 
1600 Clifton Road NE, MS A19, Atlanta, GA 30329. ytsai@cdc.gov. 
The findings and conclusions of this paper are those of the author and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
The author declares no conflict of interest.
HHS Public Access
Author manuscript
Med Care. Author manuscript; available in PMC 2019 January 01.
Published in final edited form as:
Med Care. 2018 January ; 56(1): 54–61. doi:10.1097/MLR.0000000000000844.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
services such as dental care and well-child care, publicly insured children had better or 
equivalent access than low-income children with private insurance.1–3 Nevertheless, publicly 
insured children tend to have worse access to specialty care and lower vaccination coverage 
than privately insured children.7–10
There has been concerns regarding limited provider participation in Medicaid and the 
resulting barriers to medical care among Medicaid beneficiaries.11,12 Low Medicaid 
reimbursements have been cited as one of the major reasons for low physician participation.
13,14
 Although Medicaid reimbursements are generally lower than the payment in Medicare 
and private insurance, the gap in fees is particularly large for immunization services.
The Advisory Committee on Immunization Practices (ACIP) currently recommends routine 
vaccination of 14 vaccines for children 0–18 years. Children are recommended to initiate 9 
vaccine series before 2 years old, 3 vaccines are targeted at adolescents aged 11–12 years, 
and annual influenza vaccination is recommended for all children.15 Medicaid-eligible 
children 18 years and below are eligible for the Vaccines for Children (VFC) program, a 
state-operated federal entitlement program supplying VFC-enrolled providers with ACIP-
recommended vaccines at no cost.16 Providers are reimbursed for administering vaccines for 
children enrolled in Medicaid and the amount differs across states. In 2012, the state 
regional maximum fee, the maximum amount that a VFC-enrolled provider could charge for 
administering a dose of vaccine in each state, ranged from $13 to $18 according to the 
Centers for Medicare and Medicaid Services (CMS). However, the actual payment to 
providers is determined by the state, which in many states was substantially lower than the 
regional maximum fee set by the CMS. For example, in 2012 the maximum fee and the 
actual payment to providers were $15 and $5 in Iowa, $17 and $8 in Michigan, and $15 and 
$3 in New Hampshire.
Glazner et al17 surveyed 10 private pediatric practices in Denver, Colorado where practices 
were paid on a fee-for-service (FFS) basis and concluded that the total cost per vaccine 
injection (excluding vaccine costs) averaged $11.5 in 2007. According to the 2012 Medicaid 
Analytic eXtract (MAX),18 the Medicaid vaccine administration fee in at least 21 states was 
<$11. Insufficient reimbursements to vaccinate VFC-eligible children are a disincentive for 
providers to take part in the program.19 Missed opportunities during well-child or sick visits 
are a well-documented barrier to childhood vaccination20 and efforts made by providers 
have been proven to be effective in improving vaccination coverage.21,22
Many studies have shown a positive relationship between reimbursement rates and access to 
care among Medicaid beneficiaries.14,23,24 Yet, research evaluating the link between 
payment for vaccine administration and immunization service utilization in Medicaid is 
limited. To our knowledge, only 1 study has formally looked at the link. Yoo et al25 used the 
2006–2008 National Immunization Surveys (NISs) and showed that a $10 increase in 
Medicaid reimbursements was associated with a 6.0, 9.2, and 6.4 percentage points (PPs) 
increase in influenza vaccination rate in the 2006, 2007, and 2008 NISs, respectively. 
Nevertheless, their study considered only 1 vaccine type as the service utilization measure 
and included Medicaid-eligible children aged 6–23 months.
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This study examined the relationship between Medicaid vaccine administration fees and the 
receipt of immunization services among children enrolled in a Medicaid FFS plan. It adds to 
the literature in the following perspectives: first, this study used the CMS Medicaid 
insurance claims data. In addition to the merit of including a large number of Medicaid 
enrollees, it included children of all ages who actually enrolled in Medicaid and was able to 
include all ACIP-recommended vaccines as the measure of children’s use of immunization 
services. Moreover, Yoo and colleagues used the 2005 and 2007 Medicaid fees obtained 
from the CMS unpublished data and they were unable to address a potentially important 
confounder, state-specific factors, as state dummy variables were perfectly collinear with 
state reimbursement rates. Our study calculated Medicaid reimbursement rates in each state 
for the most recent 5 years and was able to address the potential biases from state-specific 
factors. Finally, we used 2 outcome variables to capture changes in immunization service 
utilization: whether the child made ≥ 1 vaccination visit and the number of vaccination visits 
in the year. These variables allow us to gain insights into the mechanisms behind the 
findings (ie, whether changes in service utilization were driven by the number of children 
who made ≥1 vaccination visit, by the frequency of their visits among those who already 
made a visit, or both).
The goal of the study is to answer the following questions: what are the differences in 
vaccine administration reimbursements among Medicaid, Medicare, and private insurance? 
Whether and to what extent state Medicaid vaccine administration fees affect immunization 
service utilization among Medicaid-enrolled children? Would children’s access to 
immunization services improved if the Medicaid fees were changed to the Medicare level? 
And lastly, we examined whether and to what extent the Medicaid relative to private 
insurance reimbursement rates affect children’s use of immunization services as the rates are 
likely to affect providers’ decision on whether to accept Medicaid children (a lower rate 
indicated that private insurance reimbursements were more generous than Medicaid 
reimbursements).
Vaccine administration was one of the services eligible for the Medicaid fee bump (ie, a 2-
year increase in Medicaid reimbursements for some primary care services beginning in 
2013). The fee bump raised the regional maximum fees and required the state to pay the 
lesser of the updated maximum fees or the Medicare fee schedule rate.26 Our findings could 
have important policy implications and expand our knowledge on the association between 
Medicaid reimbursements and children’s access to preventive care.
METHODS
This study used data from the 2008–2012 MAX system, generated by the CMS.18 The MAX 
contains individual-level enrollment information and medical claims records for Medicaid 
beneficiaries in the 50 states and the District of Columbia (5 states—Colorado, Idaho, 
Kansas, Maine, and Rhode Island—were excluded because of missing data in 2011 and 
2012). More recent data are available, but limited to only 20 states in 2013 and 11 states in 
2014.
Tsai Page 3
Med Care. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Children 0–17 years and continuously enrolled in a Medicaid FFS insurance plan for the 
entire study year were included (excluding ~80,000 children). The analyses were restricted 
to FFS enrollees to examine the association between Medicaid payments to providers and 
immunization service utilization. In managed-care arrangements, states contract with 
managed-care organizations (MCOs) to provide a defined set of services for beneficiaries 
and payment usually occurs on a capitated per-beneficiary per-month basis. Accordingly, 
FFS-based reimbursements do not apply to children in managed-care plans and providers 
serving Medicaid enrollees in a managed-care plan would be less likely to respond to 
changes in FFS-based reimbursements for vaccine administration compared with providers 
serving Medicaid enrollees in a FFS plan.
To ensure the number of children included in each state was sufficiently large and consistent 
across years, the analysis was restricted to states with a Medicaid managed-care penetration 
(MCP) rate <75% in each of the 5 study years (ie, Alaska, Florida, Minnesota, Missouri, 
New Hampshire, Virginia, West Virginia, and Wyoming).27 In 2008–2012, about 19% of the 
Medicaid-enrolled children 0–17 years enrolled in a FFS plan and the study population 
represented about 24% of the Medicaid FFS children in the United States. The state 
Medicaid MCP rate referred to the percentage of continuously enrolled children aged 0–17 
years enrolled in a managed-care plan, which was calculated using the MAX by the author.
Linear regressions were used to examine the association between state vaccine 
administration fees and utilization of immunization services among children. Two variables 
were used to capture immunization service utilization: whether the child had made ≥ 1 
vaccination visit and the number of vaccination visits in the year. A vaccination visit was 
defined as an outpatient visit with the International Classification of Diseases-9th Revision 
(ICD-9) or Current Procedural Terminology (CPT) codes related to vaccines. The main 
independent variable is state Medicaid vaccine administration fees, which were calculated as 
the mode value of the Medicaid reimbursements for vaccination visits in each state and year 
(Appendix Table A1). To verify the payment amount generated from the MAX, the mode 
values were compared with the numbers reported in Medicaid Reimbursement Report by 
American Academy of Pediatrics.28
The Medicare and private insurance fees were estimated using the 2008–2012 CMS 
Medicare data29 and the 2008–2012 MarketScan Commercial Claims and Encounters 
(CCAE) Database.30 The study population were continuously enrolled beneficiaries who 
resided in the 8 states and were at least 65 years in the Medicare data and 0–17 years in the 
CCAE. We focused on the FFS claims for vaccination visits and used the mode value of the 
insurance payment for the vaccination visits as our payment variables. Subsequent analyses 
used the ratio of Medicaid to private insurance payment for vaccine administration as the 
key independent variable to measure the generosity of Medicaid relative to private insurance 
fess.
All regressions used robust SEs clustered at the state level to account for the 
nonindependence of observations within the same state over time and were adjusted for age 
group (0–3, 4–6, 7–10, and 11–17 y), sex (males vs. females), and race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic, and non-Hispanic other race). The 
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regressions controlled for state unemployment rate,31 state Medicaid MCP rate, year-fixed 
effects (accounting for national trends in the use of immunization services), and state-fixed 
effects (accounting for state-specific factors that affected state vaccine administration fees 
and children’s access to immunization services). As described above, providers serving 
managed-care patients were less likely to be responsive to changes in Medicaid 
reimbursements than providers serving FFS patients. If a large proportion of the Medicaid 
enrollees in the state were covered by managed-care plans, the estimated effects of the FFS-
based reimbursement rates on immunization service utilization should be smaller. One 
possible reason may be that providers with a large proportion of their Medicaid patients in 
managed care may follow the same standard of care for all patients and be less concerned 
about reimbursement rates for a relatively smaller portion of their patients. To allow for 
differential effects of Medicaid fees by state Medicaid MCP rates and avoid potential biases, 
we followed previous studies to include an interaction term of vaccine administration fees 
and state Medicaid MCP rate in the regression equation.25,32 Subsequent analyses stratified 
the study population by age group to examine whether the estimated effect differed 
according to age.
Three sensitivity analyses were performed. First, we calculated state vaccine administration 
fees excluding vaccination visits with the CPT codes indicating an additional vaccine dose 
(ie, 90461, 90466, 90468, 90472, and 90474). Second, we used $10 (as opposed to $14) as 
the vaccine administration fee for Wyoming as the state pays $10 for children ≥ 8 years and 
$14 for children under 8 years. Finally, identification of the effect of Medicaid fees came 
from changes in fees within states over time as state-fixed effects were included in the 
regression. Our data showed that Alaska and Minnesota experienced fee increases during 
2008–2012. We included 34 states in the sensitivity analysis by relieving the sample 
restriction of including states with a MCP rate <75% (states with a large variation in the 
number of FFS enrollees across years were excluded). Among the 34 states, 14 states 
experienced fee changes during 2008–2012. Statistical analyses were performed using Stata 
software, version 13 (Stata Corporation, College Station, TX).
As an analysis of secondary data without identifiers, the study did not require institutional 
review board review.
RESULTS
State Vaccine Administration Fees
Table 1 displays the reimbursement rates for vaccine administration in Medicaid, Medicare, 
and private insurance by state and year. The table demonstrates large variations in fees 
across states and shows that Medicaid payments for vaccine administration were lower 
compared with the payment amount in Medicare and private insurance except for the state of 
Alaska. In 2008, Medicaid reimbursements for vaccine administration in the remaining 7 
states averaged about 50% of the Medicare fees and the number was 45% in 2012; the 
corresponding numbers for private insurance were 62% in 2008 and 49% in 2012.
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Study Population
A total of 1,678,288 Medicaid-enrolled children were included, ranging from 286,641 to 
372,139 per year. In 2008–2012, the average percentage of children who had ≥1 vaccination 
visit in the year was 31%; the mean number of vaccination visits was 0.9. In each year, about 
60% were between 0 and 10 years old, about 53% were males, and over 67% were non-
Hispanic white (Table 2).
Vaccine Administration Fees and Utilization of Immunization Services
Table 3 shows the regression results of children’s use of immunization services on state 
Medicaid vaccine administration fees. Children aged 4–6, 7–10, and 11–17 years were about 
15, 32, and 27 PPs less likely to have made a vaccination visit than children aged 0–3 years 
(P < 0.01). Males were about 1 PP less likely to have made a vaccination visit than females 
(P < 0.01). For every 1 PP point increase in the state MCP rate, the probability that a child 
had made a vaccination visit increased by 0.56 PP [95% confidence interval (CI), 0.15–0.97; 
P < 0.05].
The coefficient on Medicaid vaccine administration fees is 0.72 (95% CI, 0.23–1.21; P = 
0.01), meaning that the probability of children having made a vaccination visit in the year 
would increase by 0.72 PP (an increase of 2% from the mean) if the state increased 
Medicaid payment by $1. As expected, coefficients on the interaction term between 
Medicaid fees and state MCP rates show that changes in vaccine administration fees were 
differentially negatively associated with state MCP rates (−0.02; 95% CI, −0.03 to −0.01; P 
= 0.001). The result indicated that the estimated effect of Medicaid fees on the use of 
immunization services was smaller if the state had a higher MCP rate. The estimated effect 
of Medicaid fees on the number of vaccination visits was 0.03 (95% CI, −0.00 to 0.06; P = 
0.06), indicating that higher payment was associated with increasing number of vaccination 
visits. For the probability of children having had a vaccination visit in the year, the 
coefficient on the Medicaid fees was the highest when we restricted the study population to 
children aged 0–3 years (1.34 PPs; P < 0.05) and the estimated effect was small and 
statistically insignificant (−0.18 PP; P = 0.21) when we restricted the study population to 
children aged 7–10 years.
In Table 4, we used the parameters estimated from the regression model in Table 3 to 
estimate changes in the probability of children having made a vaccination visit in the year if 
the state changed its Medicaid reimbursements to the Medicare level. Columns (2) and (3) of 
Table 4 shows the mean reimbursement rates in the state for the Medicaid and Medicare 
program in 2008–2012, respectively. In the state of New Hampshire, where the difference 
between the Medicare and Medicaid fee was the largest ($19), increasing payment from the 
Medicaid to the Medicare level would increase the probability that a child had made a 
vaccination visit by 14.26 PPs (95% CI, 4.58–23.93; P < 0.05), an increase of 30.1% from 
the mean percentage in the state. In the state of Wyoming, where the difference between the 
Medicare and Medicaid fee was the smallest ($7), reimbursing Medicaid-participated 
providers at the Medicare rate would increase the probability by 5.10 PPs (95% CI, 1.64–
8.57; P < 0.05), an increase of 12.4% from the mean percentage in the state.
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Using the ratio of Medicaid to private insurance fees as the main independent variable, the 
estimated effect on the probability of children having made a vaccination visit was positive 
(0.06 PP, 95% CI, −0.00 to 0.12; P < 0.1) (Table 5). The estimated effect increased 
considerably if the analysis was restricted to 4 states with a MCP rate <0.4 (0.17 PP, 95% 
CI, 0.02–0.31; P < 0.05). The result indicated that for every 1% increase in the ratio of 
Medicaid to private insurance fees, the probability of children making ≥ 1 vaccination visit 
would increase by 0.17 PP in states with a MCP rate <0.4.
Sensitivity Analysis
Results did not change when using $10 as the administration fees in Wyoming. Excluding 
vaccination visits during which an additional vaccine dose was administered did not change 
the mode value of state Medicaid vaccine administration fees. The results were similar to the 
baseline results (0.72 PP, P < 0.05; 0.03, P = 0.06) when including FFS enrollees in 34 states
—the estimated effect of Medicaid fees on the probability of children having made a 
vaccination visit in the year was 0.45 (95% CI, 0.00–0.89; P < 0.05) and was 0.01 (95% CI, 
−0.00 to 0.03; P = 0.15) for the number of vaccination visits.
DISCUSSION
A total of 1,678,288 children enrolled in a Medicaid FFS plan and resided in the 8 states 
were included. In 2008–2012, 31% of these children made ≥ 1 vaccination visit in the year 
and the mean number of visits in the year was 0.9. State Medicaid payment for vaccine 
administration was positively associated with immunization service utilization; for every $1 
increase, the probability of children making ≥ 1 vaccination visit increase by 0.72 PPs (95% 
CI, 0.23–1.21; P = 0.01). The estimated effect of Medicaid fees was larger among children 
aged 0–3 years compared with children in other age groups. Using the ratio of Medicaid to 
private insurance fees to measure the generosity of Medicaid reimbursements, the estimated 
effect was positive and statistically significant (0.17, 95% CI, 0.02–0.31; P < 0.05) in 4 
states with a MCP rate <0.4.
Our findings suggest that increasing Medicaid reimbursements for vaccine administration 
could improve immunization services utilization among Medicaid-enrolled children. 
Increases in the probability of children making ≥ 1 vaccination visit indicated that Medicaid 
fees were positively associated with the number of children making a vaccination visit, 
which could be that higher payments attract more providers to accept Medicaid children 
and/or encourage Medicaid-participating providers to vaccinate current Medicaid children. 
Increases in the number of vaccination visits indicated that children having made a visit 
increased the frequency of their visits, which could be that providers make efforts to 
vaccinate current patients due to higher payments. Overall, our results suggest that 
increasing Medicaid reimbursement rates could be effective in reducing missed opportunities 
in the office settings.
Medicaid MCP has increased over the years, from 71% in 2008 to 77% in 2014.33 Given 
that managed care usually emphasizes primary care services and providers with a large 
proportion of their Medicaid patients in managed care may follow same standard of care for 
all their patients, it is not surprising to find a positive association between state MCP rates 
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and the probability of children having made a vaccination visit in the year. In Medicaid 
managed-care plans, MCOs receive per-member per-month capitated payments for 
providing medical services to beneficiaries and thus changes in FFS-based reimbursement 
rates would be unlikely to affect the payment amount to providers serving managed-care 
patients. Consistent with the expectation, our findings showed that the estimated effect of 
state Medicaid reimbursement rates decreased with state MCP rates and the payment gap 
between Medicaid and private insurance was an important factor influencing Medicaid 
patients’ access to immunization services only in states with a low MCP rate.
The study has potential limitations. First, unobserved factors may simultaneously affect 
children’s immunization service use and Medicaid vaccine administration fees, which in turn 
would bias the estimate. However, our regressions controlled for state and year-fixed effects, 
which accounted for state-specific characteristics and year trends in immunization service 
use. The omitted-variable bias should not play a key role in the findings. Second, the study 
focused on Medicaid FFS insurance claims and thus the results do not apply to the payment 
structure in Medicaid managed-care programs. As discussed above, MCOs negotiate 
payment and service contracts with state Medicaid agencies and thus methods used to 
analyze providers’ responses to payment changes in managed-care arrangements would be 
entirely different from that in FFS arrangements. Moreover, to our knowledge, none of the 
existing datasets could be used to analyze the financial incentives among providers serving 
Medicaid managed-care patients.
CONCLUSIONS
Routine childhood immunization program is one of the most cost-effective disease 
prevention programs; every dollar spent in routine childhood immunization ultimately saves 
at least $10.34 Insufficient reimbursements for immunization services remain one of the 
major concerns among physicians. This study shows a predicted improvement in access to 
immunization services among children in Medicaid FFS plans if Medicaid reimbursement 
rates were raised to the Medicare level. Nevertheless, while it is important to address the 
payment gap, to effectively improve physicians’ willingness to accept Medicaid patients, 
state Medicaid agencies should address other barriers cited by physicians, such as long 
waiting time for reimbursements, complicated administrative processes, and low acceptance 
referrals by specialists.35
APPENDIX
TABLE A1
Codes to Identify Vaccination Visits and Details Regarding State Vaccine Administration 
Fees
Variables Codes/Descriptions
Vaccination visits 90460–90461 and 90471–90474: Vaccine administration
90632–90636, 90730: Hepatitis A
90636, 90697, 90723, 90731, 90739–90740, 90743–90748: Hepatitis B
90644–90648: Haemophilus influenza b (Hib)
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Variables Codes/Descriptions
90649–90651: Human Papilloma virus (HPV)
90653–90668, 90672–90673, 90685–90688: Influenza virus vaccine
90669–90670: Pneumococcal conjugate vaccine
90680–90681: Rotavirus vaccine
90696: Diphtheria, tetanus toxoids, acellular pertussis vaccine and poliovirus vaccine, inactivated 
(DTaP-IPV)
90697: Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, 
haemophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-
Hib-HepB)
90698: Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus influenza type B, 
and poliovirus vaccine, inactivated (DTaP-Hib-IPV)
90700–90703, 90714–90715, 90718: Diphtheria, tetanus toxoids, and pertussis vaccine
90705: Measles virus vaccine
90706: Rubella
90707–90708: Measles and rubella virus vaccine
90710: Measles, mumps, rubella, and varicella vaccine (MMRV)
90716: Varicella virus vaccine
90720: Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and haemophilus influenza B 
vaccine (DTP-Hib)
90721: Diphtheria, tetanus toxoids, and acellular pertussis vaccine and haemophilus influenza B 
vaccine (DTaP-Hib)
90723: Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus 
vaccine, inactivated (DTaP-HepB-IPV)
90732: Pneumococcal polysaccharide vaccine (PPSV)
90733: Meningococcal polysaccharide vaccine (MPSV)
90734: Meningococcal conjugate vaccine (MCV4)
State vaccine 
administration fees
The data included 13,854,130 insurance claims for vaccination visits made by 1,678,288 
Medicaid-enrolled children aged 0–17 years, continuously enrolled in a Medicaid fee-for-service 
plan, and resided in the 8 states with a MCP rate <75%. We used the mode value of the Medicaid 
payment for the vaccination visit in each state and year as the state vaccine administration fees
MCP indicates managed-care penetration.
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TABLE 3
State Vaccine Administration Fees and Utilization of Immunization Services by Children, 2008–2012 
Medicaid Analytic eXtract
N=1,678,288
At Least 1 Vaccination Visit
in the Year
PPs (95% CI)
No. Vaccination Visits
in the Year
Coefficients (95% CI)
State vaccine administration fee 0.72 (0.23–1.21)** 0.03 (−0.00 to 0.05)*
State vaccine administration fees×MCP rate
−0.02 (−0.03 to −0.01)*** −0.00 (−0.00 to 0.00)*
Age group (reference: 0–3 y)
4–6
−14.67 (−18.57 to −10.77)*** −1.40 (−1.71 to −1.08)***
7–10
−32.17 (−38.05 to −26.28)*** −2.00 (−2.49 to −1.52)***
11–17
−27.40 (−33.14 to −21.67)*** −1.82 (−2.29 to −1.36)***
Males
−1.48 (−2.26 to −0.70)*** −0.04 (−0.07 to −0.01)***
Race/ethnicity (reference: non-Hispanic other race)
Non-Hispanic white −1.88 (−8.12 to 4.36) 0.04 (−0.15 to 0.22)
Non-Hispanic black 0.73 (−7.71 to 9.17) 0.07 (−0.27 to 0.40)
Hispanic −0.38 (−9.29 to 8.54) 0.05 (−0.24 to 0.34)
State MCP rate 0.56 (0.15–0.97)** 0.02 (−0.01 to 0.04)
State unemployment rate 0.43 (−2.06 to 2.91) 0.02 (−0.13 to 0.18)
Constant 19.29 (−9.33 to 47.91) 0.96 (−0.98 to 2.90
The analysis included 1,678,288 Medicaid-enrolled children aged 0–17 years, continuously enrolled in a Medicaid fee-for-service plan, and resided 
in the 8 states with a MCP rate <75%. All regression models included age group, sex, race/ethnicity, state MCP rate, state unemployment rate, and 
state and yearfixed effects as control variables.
CI indicates confidence interval; MCP, managed-care penetration; PP, percentage point.
*P < 0.1.
**P < 0.05.
***P < 0.01.
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TABLE 5
Medicaid Relative to Private Insurance Fees and Utilization of Immunization Services by Children
N =1,678,288† State MCP Rate <0.4 (N =645,243)‡
At Least 1 
Vaccination Visit
in the Year
PP (95% CI)
No. Vaccination 
Visits
in the Year
Coefficients (95% 
CI)
At Least 1 Vaccination 
Visit
in the Year
PP (95% CI)
No. Vaccination Visits
in the Year
Coefficients (95% CI)
(Medicaid fees/private fees)×100 0.06 (−0.00 to 0.12)* 0.00 (−0.00 to 0.01) 0.17 (0.02–0.31)** 0.01 (0.00–0.01)**
Age group (reference: 0–3 y)
  4–6 −14.67 (−18.59 to 
−10.76)***
−1.40 (−1.71 to 
−1.08)***
−16.57 (−23.48 to 
−9.65)***
−1.36 (−1.85 to −0.87)***
  7–10 −32.17 (−38.07 to 
−26.28)***
−2.01 (−2.49 to 
−1.52)***
−34.36 (−43.83 to 
−24.89)***
−1.86 (−2.48 to −1.24)***
  11–17 −27.41 (−33.16 to 
−21.66)***
−1.82 (−2.29 to 
−1.36)***
−29.23 (−40.45 to 
−18.02)***
−1.66 (−2.14 to −1.19)***
Males −1.43 (−2.20 to 
−0.65)***
−0.04 (−0.07 to 
−0.01)***
−1.92 (−3.39 to −0.45)** −0.05 (−0.11 to −0.00)**
Race/ethnicity (reference: non-Hispanic other race)
  Non-Hispanic white −1.91 (−8.15 to 4.33) 0.04 (−0.15 to 0.22) −0.98 (−11.73 to 9.78) 0.08 (−0.22 to 0.38)
  Non-Hispanic black 0.71 (−7.74 to 9.15) 0.07 (−0.27 to 0.40) 6.47 (−6.94 to 19.88) 0.25 (−0.09 to 0.59)
  Hispanic −0.46 (−9.30 to 8.37) 0.04 (−0.24 to 0.33) 2.21 (−13.52 to 17.95) 0.13 (−0.31 to 0.57)
State MCP rate 0.36 (−0.02 to 0.74)* 0.01 (−0.01 to 0.03) 0.23 (0.07 to 0.39)** 0.01 (0.00 to 0.02)**
State unemployment rate 0.35 (−1.72 to 2.43) 0.02 (−0.11 to 0.14) −1.33 (−6.42 to 3.76) −0.06 (−0.30 to 0.18)
All regressions included age group, sex, race/ethnicity, state MCP rate, state unemployment rate, and state and year-fixed effects as control 
variables.
†
The analysis included Medicaid-enrolled children aged 0–17 years, continuously enrolled in a Medicaid FFS plan, and resided in the 8 states with 
a MCP rate <75%.
‡
The analysis included Medicaid-enrolled children aged 0–17 years, continuously enrolled in a Medicaid FFS plan, and resided in the 4 states with 
a MCP rate <40%.
CI indicates confidence interval; FFS, fee-for-service; MCP, managed-care penetration; PP, percentage point.
*P < 0.1.
**P < 0.05.
***P < 0.01.
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